NASDAQ OMX

First Medical Patent Issued for the Oculenz(TM) Augmented Reality Glasses

Dela

Ocutrx(TM) AR Glasses Garners First Medical Patent for Restoring Functional Sight to Patients with Visual Field Deficits

IRVINE, Calif., June 12, 2018 (GLOBE NEWSWIRE) -- Ocutrx Vision Technologies, LLC, a California based Augmented Reality (AR) Glasses developer today announced that the company's core AR medical application technology has been issued its first patent by the United States Patent and Trademark Office (USPTO). The company's Augmented Reality headset, called Oculenz(TM) boasts the widest field-of-vision in the industry, with a 110-degree high-resolution heads-up display, in a wirelessly connected, untethered, micro-weight headset.  The patent also teaches how the Oculenz ARwear(TM) can work in conjunction with smart contact lenses as the display and eye-tracking. 

"This first patent award validates our core technology for using our AR platform innovations for medical applications," stated Michael H. Freeman, CEO/CTO and Founder of Ocutrx. "This is a real milestone for creating value for Ocutrx's patent portfolio and an incredible step forward in securing patent rights around the world," Freeman said. "We immediately filed a Continuation Patent to focus on the previously filed specification elements incorporating eye-tracking with an AR head mounted display for the larger AR market."  

The company plans to also market their Oculenz to other sectors including gaming, commercial, industrial, HAZMAT, e-commerce, aerospace, drones and defense.  "While many AR companies built a platform first, and are now looking to find a market," said Scott Evans, M.B.A., Ocutrx COO, "we strategically designed our first ARwear for the medical industry, where there are many highly-motivated buyers, then we intent to expand into the AR market-at-large." 

Ocutrx was founded in 2015 by Michael H. Freeman, an Emmy Award-winning designer of streaming mobile video technology which became the basis for the IEEE 802.11(n) MIMO standard.  Freeman created the first streaming smart-phone video product which was licensed by virtually all of the cell companies which existed in the 1990's.  The streaming video technology and patents were later sold to Samsung Electronics. 

"The Oculenz is the first ground-breaking technology to offer a solution for advanced central visual defects in patients with retinal disease," said Dr. Thomas Finley, M.D. a Vitreoretinal surgeon and member of the Ocutrx International Medical Advisory Board (IMAB). "This innovative AR device brings a new hope to regain functional vision previously considered impossible. The impact on the individual's quality of life and retained or regained ability to productively function at home and in the workplace will be immeasurable."

The USPTO determined that Ocutrx's first patent application was allowable covering a diagnostic phase where the patients can wear the Oculenz to map their own retinal defects, alone or with the help of their physicians, and a second corresponding display phase where the video is buffered according to the retinal map and displayed over the patient's real-world vision. The Oculenz's buffered display shows all the real-world video image, but none is shown on the exact area of the patient's eye defect.  Instead, it is directed to the patient's existing good areas of the macula or near adjacent peripheral retina.

"The Oculenz technology works somewhat like how we all have a natural blind spot in our vision that we do not realize on a day to day basis," said Dr. Lars Freisberg, M.D., an international Retinal Specialist surgeon, licensed in the U.S., Norway and Germany, and member of the Ocutrx IMAB. "However, you never really see this hole," explained Dr. Freisberg, "because the brain fills it in with other gathered visual information."   

"With the Oculenz the idea is that the patient senses the entire image and learns to disregard the defect area through 'neural adaptation' due to the 'plasticity of the brain,'" said Dr. R. Wade Crow, M.D., Neural Ophthalmologist and Assistant Professor of Neuro-Ophthalmology at the University of California-Irvine and member of the Ocutrx IMAB. "Working with visual input, the brain can train itself to not see redundant or unnecessary things."

About  Ocutr x

With corporate headquarters in the OC at Irvine, California, and a research and R&D lab in the Midwest, located in Oklahoma, Ocutrx is a new breed of AR manufacturing company focusing on the lightest weight headset with the largest field-of-vision in the market. At a time when worldwide applications for easy-to-wear and easy-to-use AR solutions are being touted as the "next big thing after the smartphone" Ocutrx is creating impactful, revolutionary "AR glasses for the masses"(TM).   

To learn more about Ocutrx, please visit the company website at www.ocutrxarwear.com.

Media Contact: 
Karen Clarke
Media Representative
Ocutrx Vision Technologies, LLC
karen.clarke@ocutrxarwear.com
(949) 623-8408

Photos accompanying this announcement are available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/03bd1b8e-4d74-4836-b372-a1aa0f110ddd http://www.globenewswire.com/NewsRoom/AttachmentNg/6eeb0bdf-925b-48e8-995c-589429b422f2




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ocutrx Vision Technologies, LLC via Globenewswire

Om

NASDAQ OMX
NASDAQ OMX



Följ NASDAQ OMX

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från NASDAQ OMX

BIMobject AB: Kallelse till extra bolagsstämma den 5 september 2018. Patrick Söderlund och Hjalmar Winbladh föreslås som nya styrelseledamöter i BIMobject AB. Split 2:1 föreslås.15.8.2018 15:30Pressmeddelande

Aktieägare representerande cirka 49 procent av rösterna i BIMobject AB har meddelat att de föreslår att Hjalmar Winbladh och Patrick Söderlund väljs till nya styrelseledamöter vid en extra bolagsstämma onsdagen den 5 september 2018. Ben O'Donnell lämnar sitt uppdrag som styrelseledamot i samband med den extra bolagsstämman. Styrelsen kommer därefter att bestå av Stefan Larsson (VD), Anders Wilhjelm (ordförande), Johannes Reischböck, Philippe Butty, Hjalmar Winbladh och Patrick Söderlund. Vidare föreslås ändrad ersättning till styrelsen. Nytt arvode utgår med 800 000 kronor, fördelat mellan styrelseordförande och Söderlund om 400 000 kronor vardera. Styrelsen föreslår även att stämman beslutar om aktieuppdelning av befintliga utestående aktier i förhållande 2:1. Patrick Söderlund, född 1973 och svensk medborgare, är Chief Design Officer samt Executive Vice President på Electronic Arts. I denna roll leder han utvecklingen av bolagets tekniska innovationer och bolagets marknadsföringsteam

BIMobject AB: Notice to attend Extraordinary General Meeting on September 5, 2018. Patrick Söderlund and Hjalmar Winbladh proposed as new Board Members in BIMobject AB. A split 2:1 is proposed.15.8.2018 15:30Pressmeddelande

Shareholders representing approximately 49 percent of the votes in BIMobject AB have announced that they propose that Hjalmar Winbladh and Patrick Söderlund are appointed new Board Members at an Extraordinary General Meeting to be held on Wednesday September 5, 2018. Ben O'Donnell resigns as Board Member in connection with the Extraordinary General Meeting. The Board will thereafter be composed of Stefan Larsson (CEO), Anders Wilhjelm (Chairman), Johannes Reischböck, Philippe Butty, Hjalmar Winbladh and Patrick Söderlund. Furthermore, a change in remuneration to the Board is proposed. The new Board fee totals SEK 800,000 and is to be divided between the Chairman and Söderlund with SEK 400,000 each. The board also proposes that the General Meeting resolves to split the company's shares 2:1. Patrick Söderlund, born in 1973 and a Swedish citizen, is Chief Design Officer and Executive Vice President at Electronic Arts. In his present role he manages the development of technology innovation

BIMobject AB: Offentliggörande av delårsrapport april - juni 201815.8.2018 08:00Pressmeddelande

Den fullständiga rapporten finns även tillgänglig på bolagets hemsida (info.bimobject.com). Andra kvartalet 2018 Faktureringen ökade med 83 procent och uppgick till 33 MSEK (18). Koncernens nettoomsättning ökade med 75 procent och uppgick till 28 MSEK (16). Fördelning mellan projekt och webservices (prenumerationer) var 40/60 procent (60/40). Bruttomarginalen ökade till 86 procent (81). Koncernens rörelseresultat förbättrades och uppgick till -15 MSEK (-17). Resultat per aktie uppgick till -0,29 SEK (-0,31) före utspädning. Kassaflödet från löpande verksamheten uppgick till -18 MSEK (-15). Ackumulerat antal användare ökade och uppgick till cirka 845 000. Ackumulerat antal nedladdningar uppgick till 25,5 miljoner. Antalet tillverkare uppgick till 1230. Styrelsen beslutade att påbörja processen för notering av bolaget vid Nasdaq Stockholm. Viktiga händelser andra kvartalet BIMobject ingår samarbete med Pipe Retail Solution för att effektivisera digital butiksplanering. BIMobject tecknar

BIMobject AB: Interim Report April - June 201815.8.2018 08:00Pressmeddelande

Second quarter 2018 Billing increased by 83 percent to SEK 33 (18) million. The Group's net sales increased by 75 percent to SEK 28 (16) million. The distribution between projects and web services (subscriptions) was 40/60 (60/40) percent. The gross margin increased to 86 (81) percent. The Group's operating profit improved to SEK -15 (-17) million. Basic earnings per share amounted to SEK -0.29 (-0.31). Cash flow from operating activities was SEK -18 (-15) million. The accumulated number of users increased to approximately 845,000. The accumulated number of downloads amounted to 25.5 million. The number of manufacturers was 1,230. The Board decided to initiate the process of listing the Company on Nasdaq Stockholm. Significant events during the second quarter BIMobject forms strategic partnership with Pipe Retail Solution to streamline digital planning of retail spaces. BIMobject signs Letter of Intent with leading US 3D media company Matterport. CEO's comments EQT Ventures' investment

Immunicum AB (publ) to Present Preclinical Data on Ilixadencel in Combination with CPIs and Immune Enhancers at ESMO 2018 Congress13.8.2018 08:00Pressmeddelande

Press Release 13 August 2018 Immunicum AB (publ) to Present Preclinical Data on Ilixadencel in Combination with CPIs and Immune Enhancers at ESMO 2018 Congress Immunicum AB (publ; IMMU.ST) announced today that the company will present a poster on its lead development candidate, ilixadencel, at the European Society for Medical Oncology (ESMO) 2018 Congress, held October 19-23, 2018 in Munich, Germany. Immunicum will announce the complete data through a press release following the presentation. The poster abstract will also be published in the ESMO 2018 Congress Abstract Book, a supplement to the official ESMO journal, Annals of Oncology. Poster Information: Title: Intratumoral administration of pro-inflammatory allogeneic, "off-the-shelf", dendritic cells in combination with anti-PD-1 or anti-CD137 has a synergistic anti-tumor effect Presentation Number: 440P Presenter: Dr. Alex Karlsson-Parra, Chief Scientific Officer Date & Time: Monday, October 22, 2018; 12.45 - 13.45 CET Location: H

Immunicum AB (publ) presenterar prekliniska data för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress13.8.2018 08:00Pressmeddelande

Pressmeddelande 13 augusti 2018 Immunicum AB (publ) presenterar prekliniska data för ilixadencel i kombination med checkpointhämmare och immunaktiverare på 2018 års ESMO-kongress Immunicum AB (publ; IMMU.ST) tillkännagav idag att bolaget kommer att presentera en poster om sin ledande produktkandidat, ilixadencel, på 2018 års kongress för European Society for Medical Oncology (ESMO) , som hålls den 19-23 oktober 2018 i München i Tyskland. Immunicum kommer att offentliggöra fullständiga data i ett pressmeddelande som följer efter presentationen. En sammanfattning av postern kommer också att publiceras i ESMO 2018 Congress Abstract Book, ett komplement till ESMO:s officiella årsbok, Annals of Oncology. Posterinformation: Titel: Intratumoral administration of pro-inflammatory allogeneic, "off-the-shelf", dendritic cells in combination with anti-PD-1 or anti-CD137 has a synergistic anti-tumor effect (Intratumoral administration av pro-inflammatoriska allogena dendritiska celler som kan lagr

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum